文献速递精神分裂症与精神病性障碍

匹莫范色林治疗精神分裂症阴性症状:北美和欧洲ADVANCE 2期随机安慰剂对照试验结果

Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.
PubMed 文献 · Lancet Psychiatry · 2021-11-30

ADVANCE是一项2期、26周、随机双盲安慰剂对照研究,纳入18-55岁以阴性症状为主的精神分裂症稳定门诊患者403例,随机接受匹莫范色林或安慰剂附加治疗。第26周NSA-16总分变化匹莫范色林组最小二乘均值-10.4 vs 安慰剂组-8.5(p=0.043,效应量0.211),作者认为效应量小,需优化剂量进一步研究。

要点

  • 匹莫范色林组第26周NSA-16总分较基线最小二乘均值下降-10.4,安慰剂组下降-8.5,p=0.043,效应量0.211。
  • 治疗中出现的不良事件两组相似:匹莫范色林组80例(40%)vs 安慰剂组71例(35%)。
  • 最常见不良事件为头痛(6% vs 5%)和嗜睡(5% vs 5%)。

核心结论

  • 以阴性症状为主的精神分裂症稳定患者接受匹莫范色林治疗后阴性症状有所减轻,但鉴于效应量小,作者认为需优化剂量进一步研究以确定该效应的临床意义。

研究设计与样本

  • ADVANCE为2期、26周、随机双盲安慰剂对照研究,在北美18个和欧洲65个共83个中心进行,按地理区域分层1:1随机分配。
  • 纳入18-55岁以阴性症状为主的精神分裂症稳定门诊患者,PANSS Marder阴性因子7项总分至少20分且至少3项≥4分或至少2项≥5分。
  • 匹莫范色林或安慰剂每日口服一次,起始剂量20 mg,研究前8周内可调整为34 mg或10 mg,之后剂量稳定至研究结束。
  • 主要终点为16项阴性症状评估(NSA-16)总分从基线至第26周的变化,在意向治疗(全分析集)中分析。

主要发现

  • 2016年11月4日至2019年4月16日随机分配403例患者至匹莫范色林组(n=201)或安慰剂组(n=202),其中400例纳入疗效分析(匹莫范色林组199例,安慰剂组201例)。
  • 第26周NSA-16总分变化匹莫范色林组最小二乘均值-10.4(SE 0.67)vs 安慰剂组-8.5(SE 0.67),p=0.043,效应量0.211。
  • 治疗中出现的不良事件:匹莫范色林组80例(40%)vs 安慰剂组71例(35%);头痛6%(n=13)vs 5%(n=10),嗜睡5%(n=11)vs 5%(n=10)。
  • 安慰剂组1例报告严重头痛(0.5%)、流涕(0.5%)、咳嗽(0.5%)和流感(0.5%);匹莫范色林组1例报告严重牙痛(0.5%),2例精神分裂症加重(1%)。
  • QTcF间期平均变化匹莫范色林组4.5 ms(SD 18.0)vs 安慰剂组0.0 ms(16.0)。

关键数值与推荐

  • 主要疗效终点NSA-16总分变化:匹莫范色林组最小二乘均值-10.4(SE 0.67)vs 安慰剂组-8.5(SE 0.67),p=0.043,效应量0.211。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出鉴于效应量小,需优化剂量进一步研究以确定该效应的临床意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Negative symptoms of schizophrenia are associated with adverse clinical outcomes, but there are few effective treatments. We aimed to assess the effects of pimavanserin, a selective 5-HT2A inverse agonist and antagonist, on negative symptoms of schizophrenia. METHODS: The ADVANCE study was a phase 2, 26-week, randomised, double-blind, placebo-controlled study of pimavanserin in stable outpatients with schizophrenia aged 18-55 years with predominant negative symptoms. Patients were randomly assigned (1:1) across 83 sites (18 in North America and 65 in Europe) to receive pimavanserin or placebo daily, added to an ongoing antipsychotic medication, per a computer-generated schedule (stratification by geographical region). Eligible patients had a score of at least 20 on the sum of seven Positive and Negative Syndrome Scale (PANSS) Marder negative factor items (and scores of ≥4 on at least three or ≥5 on at least two of negative symptom items). The starting dosage of 20 mg of pimavanserin or placebo could be adjusted to 34 mg or 10 mg within the first 8 weeks of the study, after which dosage remained stable until the end of the study. Both pimavanserin and placebo were administered orally once daily as two individual tablets (pimavanserin tablets were either 10 mg or 17 mg). The primary endpoint was change in total score using the 16-item Negative Symptom Assessment (NSA-16) from baseline to week 26. Primary outcomes were analysed in patients who received at least one dose of the study drug and had NSA-16 assessments at baseline and at least once post-baseline (full analysis set). Safety outcomes were analysed in patients who had received at least one dose of the study drug. This trial is registered with ClinicalTrials.gov, NCT02970305, and is complete. FINDINGS: Between Nov 4, 2016, and April 16, 2019, we randomly assigned 403 patients to pimavanserin (n=201; 131 [65%] male; 187 [93%] White) or placebo (n=202; 137 [68%] male, 186 (92%) White), of whom 400 were included in the efficacy analysis (199 in the pimavanserin group, 201 in the placebo group). Mean age was 37·7 years (SD 9·4) in the pimavanserin group and 36·7 (9·2) years in the placebo group. The change in total NSA-16 score from baseline to week 26 was significantly improved with pimavanserin (least squares mean -10·4 [SE 0·67]) versus placebo (least squares mean -8·5 [0·67]; p=0·043; effect size: 0·211). The number of patients with treatment-emergent adverse events (TEAEs) was similar between groups: 80 (40%) patients experienced TEAEs in the pimavanserin group and 71 (35%) in the placebo group. Most TEAEs were headache (6% [n=13] vs 5% [n=10]) and somnolence (5% [n=11] vs 5% [n=10]). One patient from the placebo group reported severe headache (0·5%), rhinorrhoea (0·5%), cough (0·5%), and influenza (0·5%). In the pimavanserin group, one patient reported severe toothache (0·5%), and two patients had worsening of schizophrenia (1%). Mean change in QTcF interval was higher with pimavanerin (4·5 ms [SD 18·0]) than with placebo (0·0 ms [16·0]). INTERPRETATION: Stable patients with predominant negative symptoms of schizophrenia showed a reduction in negative symptoms after treatment with pimavanserin. However, given the small effect size, further investigation with optimised dosing is warranted to determine the clinical significance of this effect. FUNDING: Acadia Pharmaceuticals.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Bugarski-Kirola D, Arango C, Fava M, et al. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. Lancet Psychiatry. 2021. PMID: 34861170. doi:10.1016/S2215-0366(21)00386-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。